CCA
DFTX

Conservest Capital Advisors’s Definium Therapeutics DFTX Stock Holding History

Conservest Capital Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-796
Closed -$13K – 96
2022
Q1 		$13K Sell
796
-784
-50% -$13.6K ﹤0.01% 87
2021
Q4 		$33K Buy
1,580
+17
+1% +$543 ﹤0.01% 91
2021
Q3 		$55K Hold
1,563
– – 0.01% 81
2021
Q2 		$81K Buy
+1,563
New +$82K 0.01% 81

Other funds holding DFTX

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Conservest Capital Advisors's DFTX Position: Q2 2022 in Review

Conservest Capital Advisors sold out of Definium Therapeutics (DFTX) in Q2 2022, closing a stake of 796 shares — an estimated $13K sold.

Conservest Capital Advisors first reported a position in DFTX in Q2 2021 and held it in 4 quarters. The position peaked at $81K in Q2 2021. 155 funds tracked by Wall St. Rank hold DFTX as of Q2 2022.

  • Conservest Capital Advisors reported no remaining Definium Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Conservest Capital Advisors sold 796 Definium Therapeutics shares in Q2 2022, an estimated $13K.
  • Conservest Capital Advisors first reported a position in Definium Therapeutics in Q2 2021 and held it in 4 quarters.
  • Conservest Capital Advisors's Definium Therapeutics position peaked at $81K in Q2 2021.
  • 155 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2022.

Based on Conservest Capital Advisors's 13F filing for Q2 2022, filed 13 Jul 2022.